EOEleanor A. Ochodo

Eleanor A. Ochodo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eleanor A. Ochodo has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Developing an assessment tool to measure health equity considerations of guideline development handbooks

    by Ramaa Chitale, Adam Richards, Precious Williams, Tari Turner, Stephanie Goodrick, Ana González Ramos, Christina McMillan Boyles, Deana Manassaram-Baptiste, Caleb Kimutai Sagam, Eleanor Ochodo, et al.

    Objectives: Guideline development handbooks outline the methodology that authoring organizations use to create public health and clinical practice guidelines (CPGs). We created an Equity Assessment Tool (EquAT) for guideline development handbooks to identify areas of improvement and foster conversations. Methods: Sequential phases lead to tool development and face/content validation in this mixed-methods study. In phase 1, we reviewed the literature to generate a list of “essential elements” or tasks that are part of guideline development methodology, mapped “essential elements” with relevant equity concepts, and drafted our tool for use in reviewing guideline development handbooks. In phase 2, we surveyed experts for feedback on “essential elements” and explicit language for assessing equity within the tool and refined items. We piloted and finalized the tool based on feedback. Results: We identified 18 essential elements within five domains of guideline development and created a draft EquAT. Twenty of 25 invited experts responded to the online survey for feedback on the tool. Most experts provided limited feedback, and the most common suggestion was adding clarifying language to the existing tool criteria for assessing equity. Ten experts participated in pilot testing the revised tool. We found a diversity of scores, and potential reasons might be due to the complexity of the tool, differences in equity frameworks, and a variety of expertise. We incorporated their feedback and finalized the tool. Conclusions: We developed and validated the EquAT, a tool to foster discussion among assessors about the extent of health equity considerations in guideline development handbooks.

  • Open Access

    Group B streptococcus in pregnant women and neonates in Africa: a scoping review

    by Lisa Malesi Were, Jenifer Akoth Otieno, Barbara Miheso, Lilian Mosero Mayieka, Moses Alobo, Sagam Kimutai Caleb, Eleanor Ochodo

    Introduction: Group B streptococcus (GBS) affects approximately 19.7 million pregnant women, causing about 58 300 (0.3%) infant deaths globally, with highest disease burden observed in Africa. Providing a Kenyan advisory board with evidence guiding maternal GBS priority interventions, we reviewed evidence and identified gaps on determining factors, vertical transmission rates (VTR), signs and symptoms, provision of care, burden, testing, comorbidities, sequelae, and management of maternal GBS colonisation and neonatal early-onset disease (EoD) in Africa. Methods: We searched MEDLINE, EMBASE, Web of Science and Global Index Medicus, CINAHL and SCOPUS, CENTRAL, ClinicalTrials.gov and WHO Trials Register and MedRxiv. Two independent reviewers screened studies and extraction was conducted independently. We did not assess risk of bias or methodological rigour. Results were presented descriptively. Results: Our search yielded 835 studies; we included 59. Most studies were cross-sectional (n=41, 69.5%). Studies were mainly from Eastern (n=29), Southern (n=15) and Western Africa (n=14). Participants totalled 31 544 women and 8244 neonates. Most studies (n=46, 77.9%) focused on maternal GBS colonisation, highlighting a myriad of determining factors like age below 25 years (OR 2.07). VTR ranged between 33.0% and 59.1%. Signs and symptoms included dyspareunia in pregnancy (23.3% of 279 women) and respiratory distress (OR 0.11) among neonates. Rectovaginal and/or vaginal colonisation and EoD prevalence among all neonates ranged from 1.8%–64.0% in pregnancy and 6.8%–65.1% in neonates. Nearly all studies (n=58) reported on testing criteria, mainly culture methods both in pregnancy (n=45 studies) and neonates (n=25 studies). HIV/AIDS was the most common comorbidity in women (OR range: 2.8 to 4.22). Meningitis was a common sequela in four studies, one reporting presence in 36.4% of participants. Ampicillin was the most common antibiotic reported in three studies. No evidence of maternal mortality was found. Conclusions: Most evidence concerns maternal colonisation, mainly testing and prevalence. Most research is from the Eastern, Southern and Western regions, with limited evidence from the Central and Northern regions. Main gaps are in EoD burden, maternal mortality, sequelae, comorbidity and management. Testing/reporting of GBS should be adapted. Systematic reviews on determinant factors and the effectiveness of management strategies will better inform the prioritisation of GBS interventions.


  • Open Access

    Factors influencing uptake of diagnostic test interventions for SARS-CoV-2: A qualitative review

    by Nuria S. Nwachuku, Dachi I. Arikpo, Ugo J. Agbor, Peter N. Onyenemerem, Eleanor A. Ochodo, Helen Smith, Martin Meremikwu

    Background: Diagnostic tests for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may be performed based on symptomatic presentation or for screening of asymptomatic persons. Testing can limit spread by enabling rapid identification of cases leading to containment measures. However, views regarding diagnostic test as a containment intervention vary across different settings. Aim: To synthesise the findings of qualitative studies on the perceptions and factors influencing the uptake of diagnostic test interventions for SARS-CoV-2. Setting: Healthcare facilities, care homes, communities including households. Method: We searched MEDLINE database and the (WHO) SARS-CoV-2 Research database from 01 January 2020 to 06 September 2022. Qualitative data were synthesised thematically while data for barriers and facilitators were synthesised using the SURE framework. The GRADE-CERQual approach was used to assess the confidence in each review finding, while the ENTREQ checklist was used to report the QES. The quality of included studies was assessed with the CASP tool. Results: Twenty two studies were included for QES. Two were conducted in the health facility setting, 2 in care homes, and 18 in the community. Twenty of the studies came from high-income countries, 2 from low- and middle-income countries. In all, 13 analytical and 31 descriptive themes of low to moderate quality evidence emerged; mainly around fear of contracting COVID-19, test procedure and socio-economic implications of a positive test result. Conclusion: Low to moderate quality evidence of barriers to uptake of diagnostic test were largely due to misconceptions about the interventions. Contribution: Sensitising and engaging communities and stakeholders in the healthcare system, will help mitigate the fear barrier and enhance policy coordination.


  • Open Access

    Post-exposure testing at healthcare facilities with SARS-CoV-2 transmission: A rapid review

    by Emmanuel E. Effa, Okokon Ita, Joshua Mwankon, Funmi Siyanbade, Francis Iwomi, Eleanor Ochodo, Gemma Villanueva, Martin M. Meremikwu

    Background: Post-exposure severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing following health facility outbreaks may control the spread of infection. Aim: This study aimed to assess the impact of testing for SARS-CoV-2 infection on health outcomes during healthcare facility outbreaks. Setting: This review included studies conducted at skilled nursing facilities, a cancer centre, and a geriatric psychiatric facility. Methods: We followed the methods for conducting rapid systematic reviews, searched databases from December 2019 to August 2022, assessed the risk of bias using the modified Newcastle Ottawa scale, and graded the certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. We pooled the prevalence, mortality, and hospitalisation results as appropriate. Results: Of the 3055 articles from database search, no study was eligible for inclusion as outlined in the protocol. However, eight non-comparative reports (case series) in skilled nursing facilities were included. The pooled prevalence of SARS-CoV-2 infection among residents of care homes and patients were 38% (95% confidence interval [CI] = 25% – 51%; 5 studies, 2044 participants; I2 = 94%, very low certainty evidence) and was 12% (95% CI = 6% – 19%; 5 studies, 2312 participants; I2 = 94%, very low certainty evidence) for exposed healthcare workers. The pooled mortality estimate and hospitalisation rate were 17% and 24%, respectively, (very low certainty evidence). Conclusion: There is no identified evidence for or against testing of people in healthcare facilities where there is ongoing transmission of SARS-CoV-2 infection. Contribution: The evaluation of the effectiveness of testing strategies during SARS-CoV-2 outbreaks need baseline and follow-up data from well-designed before and after studies appropriate for the setting.

  • Open Access

    Asymptomatic testing people for SARS-CoV-2 in healthcare facilities: A systematic review

    by Olabisi A. Oduwole, Glory Bassey, Grace Esebanmen, Samuel Shoyinka, Johnsolomon Ohenhen, Elise Cogo, Nicholas Henschke, Eleanor Ochodo, Martin M. Meremikwu

    Background: Asymptomatic testing involves the process whereby individuals who do not show symptoms of COVID-19 are tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection using any of the available laboratory test techniques. Aim: To evaluate the effectiveness of testing asymptomatic individuals visiting, living or working in healthcare facilities in reducing SARS-CoV-2 viral infections. Setting: Healthcare databases. Method: Electronic databases were searched and limited to English language and studies published 2020 to 02 September 2022. Following the methods for rapid systematic reviews, data were analysed using a fixed effect model, and results of the effect estimate were reported as odds ratios (OR) with their confidence intervals (CI) (95% CI). Results: Databases’ searches yielded 3065 articles after deduplication and 3 studies by searching reference lists of included articles. After screening abstracts and full text articles, 3 cohort studies were included, each with serious risk of bias. Very low certainty evidence shows a decrease in occurrence of SARS-CoV-2 infections in the asymptomatic testing group among patients going for index surgery (OR: 0.05, 95 % CI: 0.00–0.82; 501 participants; 1 study) and among long term care facility staff (OR: 0.31, 95 % CI: 0.18–0.52; 3457 participants; 2 studies, I2 = 89%) than the ‘no asymptomatic testing’ group. However, its effect on their residents was contradictory. Conclusion: There is limited quality evidence to support asymptomatic testing of individuals for SARS-CoV-2 in the prevention of virus transmission in health care settings. Contribution: In the event of a future pandemic, this review offers current evidence on the potential effects of asymptomatic testing.

  • Open Access

    Evaluating the impact of malaria rapid diagnostic tests on patient-important outcomes in sub-Saharan Africa: a systematic review of study methods to guide effective implementation

    by Jenifer Akoth Otieno, Lisa Malesi Were, Caleb Kimutai Sagam, Simon Kariuki, Eleanor Ochodo

    Objective To perform critical methodological assessments on designs, outcomes, quality and implementation limitations of studies evaluating the impact of malaria rapid diagnostic tests (mRDTs) on patient-important outcomes in sub-Saharan Africa. Design A systematic review of study methods. Data sources MEDLINE, EMBASE, Cochrane Library, African Index Medicus and clinical trial registries were searched up to May 2022. Eligibility criteria Primary quantitative studies that compared mRDTs to alternative diagnostic tests for malaria on patient-important outcomes within sub-Sahara Africa. Data extraction and synthesis Studies were sought by an information specialist and two independent reviewers screened for eligible records and extracted data using a predesigned form using Covidence. Methodological quality was assessed using the National Institutes of Health tools. Descriptive statistics and thematic analysis guided by the Supporting the Use of Research Evidence framework were used for analysis. Findings were presented narratively, graphically and by quality ratings. Results Our search yielded 4717 studies, of which we included 24 quantitative studies; (15, 62.5%) experimental, (5, 20.8%) quasi-experimental and (4, 16.7%) observational studies. Most studies (17, 70.8%) were conducted within government-owned facilities. Of the 24 included studies, (21, 87.5%) measured the therapeutic impact of mRDTs. Prescription patterns were the most reported outcome (20, 83.3%). Only (13, 54.2%) of all studies reported statistically significant findings, in which (11, 45.8%) demonstrated mRDTs’ potential to reduce over-prescription of antimalarials. Most studies (17, 70.8%) were of good methodological quality; however, reporting sample size justification needs improvement. Implementation limitations reported were mostly about health system constraints, the unacceptability of the test by the patients and low trust among health providers. Conclusion Impact evaluations of mRDTs in sub-Saharan Africa are mostly randomised trials measuring mRDTs’ effect on therapeutic outcomes in real-life settings. Though their methodological quality remains good, process evaluations can be incorporated to assess how contextual concerns influence their interpretation and implementation. PROSPERO registration number CRD42018083816.


  • Open Access

    Evaluating the impact of malaria rapid diagnostic tests on patient-important outcomes in sub-Saharan Africa: a systematic review of study methods to guide effective implementation

    by Jenifer Akoth Otieno, Lisa Malesi Were, Caleb Kimutai Sagam, Simon Kariuki, Eleanor Ochodo

    Objective To perform critical methodological assessments on designs, outcomes, quality and implementation limitations of studies evaluating the impact of malaria rapid diagnostic tests (mRDTs) on patient-important outcomes in sub-Saharan Africa. Design A systematic review of study methods. Data sources MEDLINE, EMBASE, Cochrane Library, African Index Medicus and clinical trial registries were searched up to May 2022. Eligibility criteria Primary quantitative studies that compared mRDTs to alternative diagnostic tests for malaria on patient-important outcomes within sub-Sahara Africa. Data extraction and synthesis Studies were sought by an information specialist and two independent reviewers screened for eligible records and extracted data using a predesigned form using Covidence. Methodological quality was assessed using the National Institutes of Health tools. Descriptive statistics and thematic analysis guided by the Supporting the Use of Research Evidence framework were used for analysis. Findings were presented narratively, graphically and by quality ratings. Results Our search yielded 4717 studies, of which we included 24 quantitative studies; (15, 62.5%) experimental, (5, 20.8%) quasi-experimental and (4, 16.7%) observational studies. Most studies (17, 70.8%) were conducted within government-owned facilities. Of the 24 included studies, (21, 87.5%) measured the therapeutic impact of mRDTs. Prescription patterns were the most reported outcome (20, 83.3%). Only (13, 54.2%) of all studies reported statistically significant findings, in which (11, 45.8%) demonstrated mRDTs’ potential to reduce over-prescription of antimalarials. Most studies (17, 70.8%) were of good methodological quality; however, reporting sample size justification needs improvement. Implementation limitations reported were mostly about health system constraints, the unacceptability of the test by the patients and low trust among health providers. Conclusion Impact evaluations of mRDTs in sub-Saharan Africa are mostly randomised trials measuring mRDTs’ effect on therapeutic outcomes in real-life settings. Though their methodological quality remains good, process evaluations can be incorporated to assess how contextual concerns influence their interpretation and implementation. PROSPERO registration number CRD42018083816.

  • Open Access

    Reporting and Methodological Quality of Clinical Practice Guidelines for Management of Malnutrition in the East African Community: A Systematic Review Protocol

    by Caleb Kimutai Sagam, Eddy Johnson Owino, Lisa Were, Jenifer Akoth Otieno, Moriasi Nyanchoka, Belyse Munezero, Jean M. Butoyi, Oscar Nyabenda6, Gildas Ndibanje, Jonathan Niyukuri, et al.

    Background: Clinical Practice Guidelines (CPGs), serve as a framework for healthcare professionals to support therapeutic decisions and best practices for optimising patient care. However, if the guidelines do not sufficiently address all the important components of optimal care, their quality, validity, and impact are reduced. Despite multiple interventions, cases of malnutrition are still high due to the several factors linked to them. Therefore, there is a need to establish the methodological quality of malnutrition CPGs. Objective: To review and critically appraise the methodological quality of CPGs in managing malnutrition within the East African Community (EAC). Methods: We intend to focus on Integrated Management of Acute Malnutrition (IMAM) and Community Integrated Management of Malnutrition (CIMAM) guidelines. We will also focus on guidelines written in English or French and published in the last five years from the last search date or the latest guideline available. We will search the Ministry of Health websites of the EAC countries: Tanzania, Kenya, Uganda, South Sudan, Burundi, Rwanda, and the Democratic Republic of Congo. We will also search Health associations of the respective countries and their e-repositories. Using Google Search Engine, we will use the search terms "clinical practice guidelines, "nutrition guidelines", "nutrition protocols", "health guidelines"," "IMAM", "CIMAM" and "country". Five reviewers will independently select CPGs and extract data in English and French guidelines. We will conduct a quality assessment using the online version of the AGREE II tool across six domains and using the RIGHT reporting checklist. Descriptive statistics will be analysed using STATA software version 17 (Stata Corp LLC, College TX).

  • Open Access

    A synthesis of qualitative evidence of barriers and facilitators in implementing guidelines for TB testing in healthcare settings

    by Perpetua W. Karanja, Mercy N. Mulaku, Eleanor A. Ochodo

    Introduction: The suboptimal case notification rates for tuberculosis (TB) globally could partly be due to the poor implementation of TB testing guidelines or policies. We identified, appraised and synthesized qualitative evidence exploring the barriers and facilitators to implementing TB testing guidelines. Methods: We searched electronic databases and grey literature and included studies based on predefined inclusion criteria (PROSPERO registered protocol CRD42016039790) until 9th February 2023. We used the Critical Appraisal Skills Programme tool to assess the methodological quality of the included studies. Two authors reviewed the search output, extracted data and assessed methodological quality independently, resolving disagreements by consensus. We used the Supporting the Use of Research Evidence framework to identify themes and analyse and synthesize our data. We applied the Confidence in the Evidence from Reviews of Qualitative Research approach to assess the confidence of the review findings. Results: Our search output was 6976 articles, from which we included 25 qualitative studies, mostly from low- and middle-income countries (n=19) and about national guidelines (n=22). All studies were from healthcare settings. Most barriers revolved around health system constraints involving the guidelines (low trust and adherence, ambiguous and poorly developed or adapted guidelines) and poorly resourced and organized health facilities to enable the implementation of the guidelines. Individual-level barriers included low trust and low awareness among recipients and providers of care. Donor dependence was the main socio-political constraint. These barriers were similar across all income settings except poorly resourced health facilities and social and political constraints which were only reported in low- and middle-income settings. The reported facilitators were improved trust and knowledge of guidelines, national leadership support and availability of training tools and opportunities for guidelines across all income settings. We had high confidence in most of the review findings. Conclusion: Limited guideline knowledge, trust and adherence related to poorly developed and disseminated guidelines in all income settings and poorly resourced facilities in low- and middle-income countries hinder the implementation of TB testing guidelines. This could be improved by better guideline training and adaptation and resourcing of health facilities. Trial registration: The protocol of this review was registered with the International Prospective Register of Systematic Reviews (PROSPERO), registration number CRD42016039790, and published in a peer-reviewed journal.


  • Open Access

    Diagnostic test accuracy of artificial intelligence in screening for referable diabetic retinopathy in real-world settings: A systematic review and meta-analysis

    by Holijah Uy, Christopher Fielding, Ameer Hohlfeld, Eleanor Ochodo, Abraham Opare, Elton Mukonda, Deon Minnies, Mark E. Engel

    Retrospective studies on artificial intelligence (AI) in screening for diabetic retinopathy (DR) have shown promising results in addressing the mismatch between the capacity to implement DR screening and increasing DR incidence. This review sought to evaluate the diagnostic test accuracy (DTA) of AI in screening for referable diabetic retinopathy (RDR) in real-world settings. We searched CENTRAL, PubMed, CINAHL, Scopus, and Web of Science on 9 February 2023. We included prospective DTA studies assessing AI against trained human graders (HGs) in screening for RDR in patients with diabetes. Two reviewers independently extracted data and assessed methodological quality against QUADAS-2 criteria. We used the hierarchical summary receiver operating characteristics (HSROC) model to pool estimates of sensitivity and specificity and, forest plots and SROC plots to visually examine heterogeneity in accuracy estimates. From our initial search results of 3899 studies, we included 15 studies comprising 17 datasets. Meta-analyses revealed a sensitivity of 95.33% (95%CI: 90.60–100%) and specificity of 92.01% (95%CI: 87.61–96.42%) for patient-level analysis (10 datasets, N = 45,785) while, for the eye-level analysis, sensitivity was 91.24% (95%CI: 79.15–100%) and specificity, 93.90% (95%CI: 90.63–97.16%) (7 datasets, N = 15,390). Subgroup analyses did not provide variations in the diagnostic accuracy of country classification and DR classification criteria. However, a moderate increase was observed in diagnostic accuracy in the primary-level healthcare settings: sensitivity of 99.35% (95%CI: 96.85–100%), specificity of 93.72% (95%CI: 88.83–98.61%) and, a minimal decrease in the tertiary-level healthcare settings: sensitivity of 94.71% (95%CI: 89.00–100%), specificity of 90.88% (95%CI: 83.22–98.53%). Sensitivity analyses did not show any variations in studies that included diabetic macular edema in the RDR definition, nor studies with ≥3 HGs. This review provides evidence, for the first time from prospective studies, for the effectiveness of AI in screening for RDR in real-world settings. The results may serve to strengthen existing guidelines to improve current practices.